Logan Capital Management liquidity trim and
Goldman Sachs Group sell-off resulted in the sale of hundreds of thousands of
Agilent Technologies' stocks. Despite an underperformance in the healthcare sector, the company has had strong earnings and upgraded its 2025 outlook. Q3 showed a sales surge of US$160M, causing
Agilent to raise its 2025 revenue guidance. Various companies, including
Ellsworth Advisors,
MBB Public Markets I, and
Foresight Group Ltd, injected millions into
Agilent, while others decreased their positions. Agilent CEO McDonnell has spoken at a
Bank of America conference in London and sold $249K of his stock. The company also saw a Q3 earnings beat and FDA approval boost. However, in the past week, Agilent's stock fell by 5.6%. The company has also opened a biopharma experience centre, received a high sustainability score, and Insight-affiliating CEO McDonnell shared company vision at Wells Fargo Healthcare Conference. There has been heavy institutional ownership, concentration on international revenue trends, price target cuts, and recent customer-centric growth strategies in place.
Agilent Technologies A News Analytics from Tue, 21 Jan 2025 08:00:00 GMT to Sat, 13 Sep 2025 21:12:09 GMT -
Rating 5
- Innovation 8
- Information 9
- Rumor 6
